XOMA Corporation, the biotech royalty aggregator, announced that based upon the U.S. Food and Drug Administration’s acceptance of Zevra Therapeutics’ New Drug Application for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C, XOMA will make a $1 million milestone payment to LadRx.
January 11, 2024
· 4 min read